The approval is supported by data from the phase 3 VOLGA trial.
|Videos|August 6, 2020
Telemedicine appears viable for pediatric post-op visits in urology
Julia Beth Finkelstein, MD, MPH, CPPS, and colleagues evaluated the safety and costs associated with telemedicine appointments for pediatric urologic patients.
Advertisement
Julia Beth Finkelstein, MD, MPH, CPPS, of the Columbia University Department of Urology, discusses the recent Journal of Urology
Advertisement
Related to this article
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
4
Detalimogene shows continued activity in BCG-unresponsive NMIBC
5